C3 and Hepatic fibrosis: Administration of efruxifermin for 16-weeks significantly reduced liver fat and fibrosis markers including the enhanced liver fibrosis (ELF) scores and pro-C3 in a phase 2a trial (Harrison et al., 2021b).